Yusuke Okuma

Profile Information

J-GLOBAL ID: 201501056018123496
researchmap Member ID: B000244214

Research Interests

Research Areas

Life sciences / Respiratory medicine / Thoracic Oncology

Committee Memberships

Nov, 2021 - Present

Councilor of the Steering Committee, International Thymic Malignancies Interest Group
Dec, 2020 - Present

ガイドライン検討委員会胸腺腫瘍小委員会, 日本肺癌学会
Dec, 2020 - Present

ガイドライン検討委員会放射線治療及び集学的治療小委員会, 日本肺癌学会
Apr, 2019 - Present

Protocol Review Committe (PRC) Member (Medical), Japan Clinical Oncology Group (JCOG)
Apr, 2019 - Present

プロトコール審査委員会委員, 日本臨床腫瘍研究グループ（JCOG）
Dec, 2016 - Present

Guideline Committe Member, The Japan Lung Cancer Society
Aug, 2016 - Present

Delegate member in Lung Cancer Study Group, Japan Clinical Oncology Group (JCOG)
Aug, 2016 - Present

肺がん内科グループ代表委員, 日本臨床腫瘍研究グループ (JCOG)
Dec, 2016 - Dec, 2020

ガイドライン検討委員会薬物療法及び集学的治療小委員会, 日本肺癌学会
Jan, 2016 - Mar, 2018

Protocol Review Committe (PRC) Medical Reviewer, Japan Clinical Oncology Group (JCOG)
Jan, 2015 - Mar, 2018

プロトコール審査委員会医学審査員（肺がん内科グループ）, 日本臨床腫瘍研究グループ (JCOG)

Papers

197

Patient survey on cancer genomic medicine in Japan under the national health insurance system.

Hidenori Kage, Nana Akiyama, Hyangri Chang, Aya Shinozaki-Ushiku, Mirei Ka, Junichi Kawata, Manabu Muto, Yusuke Okuma, Natsuko Okita, Katsuya Tsuchihara …

Cancer science, 115(3) 954-962, Mar, 2024
Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.

Yusuke Okuma, Shogo Nomura, Jun Sakakibara-Konishi, Yoko Tsukita, Shuji Murakami, Yukio Hosomi, Yuichi Tambo, Yoshihito Kogure, Hiroshige Yoshioka, Motohiro Tamiya …

Clinical lung cancer, Feb 8, 2024
Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database.

Yusuke Okuma, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Nobuyuki Yamamoto, Tomoya Kawaguchi …

Clinical lung cancer, Feb 2, 2024
Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations.

Yuki Takeyasu, Tatsuya Yoshida, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe

JTO clinical and research reports, 5(2) 100636-100636, Feb, 2024
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence.

Kuniko Sunami, Yoichi Naito, Yusuke Saigusa, Toraji Amano, Daisuke Ennishi, Mitsuho Imai, Hidenori Kage, Masashi Kanai, Hirotsugu Kenmotsu, Keigo Komine …

JAMA oncology, 10(1) 95-102, Jan 1, 2024
Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.

Masayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, Naoko Goto, Shigehiro Yagishita, Tatsuya Imabayashi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma …

British journal of cancer, 129(12) 2034-2034, Dec, 2023
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.

Yusuke Okuma, Kaoru Kubota, Mototsugu Shimokawa, Kana Hashimoto, Yosuke Kawashima, Tomohiro Sakamoto, Hiroshi Wakui, Shuji Murakami, Kyoichi Okishio, Kenji Hayashihara …

JAMA oncology, 10(1) 43-51, Nov 22, 2023
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.

Masayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, Naoko Goto, Shigehiro Yagishita, Tatsuya Imabayashi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma …

British journal of cancer, 129(12) 2003-2013, Sep 20, 2023
Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non-small cell lung cancer from proteomic profiling of circulating extracellular vesicles.

Masahiro Torasawa, Hidehito Horinouchi, Shigehiro Yagishita, Hirofumi Utsumi, Keitaro Okuda, Daisuke Takekoshi, Saburo Ito, Hiroshi Wakui, Saori Murata, Sawako Kaku …

Thoracic cancer, 14(29) 2909-2923, Aug 24, 2023
Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy.

Tomohiro Tanaka, Yasushi Goto, Masafumi Horie, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Hidehito Horinouchi, Noriko Motoi …

Cancers, 15(16), Aug 8, 2023
Targeting microbiome, drug metabolism, and drug delivery in oncology.

Ai Sumiyoshi, Hiroyuki Fujii, Yusuke Okuma

Advanced drug delivery reviews, 199 114902-114902, Aug, 2023
Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.

Yukiko Shimoda, Tatsuya Yoshida, Jun Miyakoshi, Masahiro Torasawa, Akiko Tateishi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto …

Cancer immunology, immunotherapy : CII, 72(8) 2613-2621, Aug, 2023
Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study.

Tomoaki Nakamura, Tatsuya Yoshida, Yuki Takeyasu, Ken Masuda, Yuki Sinno, Yuji Matsumoto, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto …

Translational lung cancer research, 12(7) 1436-1444, Jul 31, 2023
Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan.

Hidenori Kage, Katsutoshi Oda, Manabu Muto, Katsuya Tsuchihara, Natsuko Okita, Yusuke Okuma, Junko Kikuchi, Hidekazu Shirota, Hideyuki Hayashi, Toshio Kokuryo …

Cancer science, 114(7) 3041-3049, Jul, 2023
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study).

Yusuke Okuma, Shogo Nomura, Kiichiro Ninomiya, Hiroshi Gyotoku, Shuji Murakami, Yoshihito Kogure, Daijiro Harada, Kyoichi Okishio, Hiroaki Okamoto, Yasushi Goto

Future oncology (London, England), 19(22) 1515-1521, Jul, 2023
Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma.

Kanako Nishimatsu, Yuji Matsumoto, Jumpei Kashima, Tatsuya Imabayashi, Keigo Uchimura, Hideaki Furuse, Ken Masuda, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida …

Translational lung cancer research, 12(6) 1245-1255, Jun 30, 2023
Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.

Masahiro Torasawa, Tatsuya Yoshida, Yuki Takeyasu, Yukiko Shimoda, Akiko Tateishi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto …

Cancer medicine, 12(11) 12388-12401, Jun, 2023
Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer.

Kazumasa Akagi, Shigehiro Yagishita, Mayu Ohuchi, Yoshiharu Hayashi, Yuki Takeyasu, Ken Masuda, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto …

Lung cancer (Amsterdam, Netherlands), 178 247-253, Apr, 2023
Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC.

Hitomi Jo, Tatsuya Yoshida, Shigehiro Yagishita, Mayu Ohuchi, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto …

JTO clinical and research reports, 4(4) 100474-100474, Apr, 2023
肺癌病因・疫学血清エクソソームのプロテオミクス解析による局所進行非小細胞肺がんに対するデュルバルマブ肺障害のリスク因子の探索

虎澤匡洋, 藤田雄, 柳下薫寛, 堀之内秀仁, 大熊加惠, 松元祐司, 新野祐樹, 大熊裕介, 吉田達哉, 後藤悌 …

日本呼吸器学会誌, 12(増刊) 171-171, Mar, 2023

Misc.

174

【呼吸器症候群(第3版)-その他の呼吸器疾患を含めて-】腫瘍性疾患異所性性ホルモン産生腫瘍異所性ACTH症候群

大熊裕介

日本臨床, 別冊(呼吸器症候群V) 122-126, Dec, 2021
【呼吸器希少腫瘍の診断・治療の最新情報】再発胸腺上皮性腫瘍に対する治療戦略

山口曜, 大熊裕介

呼吸器内科, 40(5) 469-474, Nov, 2021
【呼吸器希少腫瘍の診断・治療の最新情報】再発胸腺上皮性腫瘍に対する治療戦略

山口曜, 大熊裕介

呼吸器内科, 40(5) 469-474, Nov, 2021
Radiotherapy for Oligometastasis 腫瘍内科からみた肺癌におけるオリゴ転移に対する放射線治療への期待

大熊裕介

肺癌, 61(6) 482-482, Oct, 2021
Long-term survival after salvage surgery for extensive disease small cell lung cancer

彌勒寺紀栄, 大熊裕介, 堀尾裕俊, 比島恒和

日本病院総合診療医学会雑誌(Web), 17(3) 287-292, May, 2021
救済手術により長期生存が得られた進展型小細胞肺癌の1例

弥勒寺紀栄, 大熊裕介, 細見幸生, 堀尾裕俊, 比島恒和

気管支学, 43(3) 292-292, May, 2021
肺癌診療ガイドラインにおける臨床諸問題高齢の進行肺がん患者はガイドライン上分けて考えるべきなのか?

大熊裕介

日本呼吸器学会誌, 10(増刊) 32-32, Apr, 2021
ドライバー遺伝子変異/転座陰性の進行非小細胞肺癌に対する複合免疫療法の選択を考える

大熊裕介

日本呼吸器学会誌, 10(増刊) 106-106, Apr, 2021
【肺がん・頭頸部がん】胸腺がんに対する分子標的治療薬の展望

大熊裕介

腫瘍内科, 27(3) 287-294, Mar, 2021
Gut microbiome as a novel biomarker among NSCLC patients treated with immune checkpoint inhibitor

Taiki Hakozaki, Yukio Hosomi, Yusuke Okuma

CANCER SCIENCE, 112 169-169, Feb, 2021
Classification and Treatment of Oligometastatic Disease in Non-Small-Cell Lung Cancer

二宮貴一朗, 大熊裕介, 海老規之, 青景圭樹, 大矢由子, 阪本智宏, 上月稔幸, 野崎要, 白井克幸, 野中哲生 …

肺癌(Web), 61(2), 2021
SMARCA4欠損肺肉腫様癌に対してPembrolizumabが奏効した1例

森田智枝, 新野祐樹, 荒川さやか, 白澤昌之, 松元祐司, 大熊裕介, 吉田達哉, 後藤悌, 堀之内秀仁, 山本昇 …

肺癌, 60(7) 1026-1026, Dec, 2020
SINGLE PIPELINE RE-ANALYSIS REVISES MICROBIOME ASSOCIATIONS WITH ANTI-TUMOR RESPONSE TO CHECKPOINT INHIBITORS

Fyza Shaikh, James White, Joell Gills, Taiki Hakozaki, Richard Corentin, Bertrand Routy, Yusuke Okuma, Mykhaylo Usyk, Abhishek Pandey, Jeffrey Weber …

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8 A409-A409, Nov, 2020
EGFR遺伝子変異陽性NSCLCにおけるコバスリキッドバイオプシー陽性率と増悪形式の検討

伊藤宗洋, 吉田達哉, 柳下薫寛, 荒川さやか, 白澤昌之, 松元祐司, 新野祐樹, 大熊裕介, 後藤悌, 堀之内秀仁 …

肺癌, 60(6) 565-565, Oct, 2020
胸部悪性腫瘍におけるがんゲノムプロファイリング検査(CGP)の実施可能性の検討

水野孝昭, 吉田達哉, 元井紀子, 松元祐司, 新野祐樹, 角南久仁子, 小山隆文, 大熊裕介, 後藤悌, 堀之内秀仁 …

肺癌, 60(6) 566-566, Oct, 2020
進行/再発肺大細胞神経内分泌癌における末梢血好中球/リンパ球比と予後および腫瘍免疫微小環境との関連

白澤昌之, 吉田達哉, 堀之内秀仁, 新野祐樹, 松元祐司, 大熊裕介, 後藤悌, 山本昇, 渡辺俊一, 大江裕一郎 …

肺癌, 60(6) 600-600, Oct, 2020
Oncomine DX Target Test CDxシステムの解析成功に関わる因子の検討

竹安優貴, 吉田達哉, 元井紀子, 新野祐樹, 松元祐司, 大熊裕介, 後藤悌, 堀之内秀仁, 山本昇, 谷田部恭 …

肺癌, 60(6) 635-635, Oct, 2020
EGFR Exon20挿入変異陽性NSCLCの臨床的特徴と治療成績

森田智枝, 吉田達哉, 白澤昌之, 増田健, 新野祐樹, 松元祐司, 大熊裕介, 後藤悌, 堀之内秀仁, 山本昇 …

肺癌, 60(6) 707-707, Oct, 2020
PDL-1陰性非小細胞肺癌における抗PD-1抗体の治療効果予測因子の検討

下田由季子, 吉田達哉, 白澤昌之, 荒川さやか, 水野孝昭, 徐仁美, 松元祐司, 新野祐樹, 大熊裕介, 後藤悌 …

肺癌, 60(6) 710-710, Oct, 2020
肺NUT carcinomaの臨床的特徴

荒川さやか, 吉田達哉, 元井紀子, 新野祐樹, 大熊裕介, 後藤悌, 堀之内秀仁, 山本昇, 松元祐司, 谷田部恭 …

肺癌, 60(6) 778-778, Oct, 2020

Presentations

ワークショップ 6：臓器障害、特殊な状況を持つ患者の化学療法：WS6-4「肺がんを中心とした非AIDS悪性腫瘍に対する化学療法」

大熊裕介

第12回日本臨床腫瘍学会学術集会, Jul 19, 2014 Invited
胸腺上皮性腫瘍に対するがん薬物療法

大熊裕介

第54回日本肺癌学会総会, Nov 22, 2013 Invited
エイズと悪性腫瘍（HIV-1感染者に合併した肺がんの国内の現状）

大熊裕介

第27回エイズ学会学術集会・総会（エイズ予防財団主催エイズ対策研究推進事業研究成果等普及啓発事業：日本エイズ学会共催一般向け公開シンポジウム）, Nov 21, 2013 Invited
ワークショップ15）胸腺腫・胸腺癌の治療：切除不能胸腺癌に対する化学療法の意義についての検討

大熊裕介

第53回肺癌学会総会, Nov 8, 2012 Invited
当院における進行・再発胸腺癌に対するCDDP+CPT-11併用化学療法8例の検討

大熊裕介

ワークショップ）第52回日本肺がん学会総会, Oct 1, 2011

Professional Memberships

Research Projects

The prospective study of blood biomarker and gut microbiota in the patients treated with immunocheckpoint inhibitors for advanced non-small cell lung cancer

Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists, Grant-in-Aid for Early-Career Scientists, Japan Society for the Promotion of Science, Apr, 2019 - Mar, 2023

Profile Information

Research Interests

Research Areas

Committee Memberships

Papers

Misc.

Presentations

Professional Memberships

Research Projects

Menu

Coauthors